UGGT1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

	Compound	Confidence	Supporting neighbours

Clinical trials — most relevant to UGGT1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity	PHASE4	COMPLETED
SGLT2 Inhibition: Uric Acid Excretion Study	PHASE4	COMPLETED
Acute Effects of an Oral Fat Load on Skeletal Muscle and Hepatic Insulin Sensitivity	PHASE4	COMPLETED
Effect of Genetic Polymorphisms of UGT on the PKs of Indapamide in Egyptians	PHASE4	UNKNOWN
Effect of Glucuronosyltransferase (UGT) Genetic Variation on Pharmacokinetics of Empagliflozin	PHASE3	COMPLETED
Vaccine Treatment for Advanced Non-Small Cell Lung Cancer	PHASE1/PHASE2	COMPLETED
OGT 918-006: A Phase I/II Randomized, Controlled Study of OGT 918 in Patients With Neuronopathic Gaucher Disease	PHASE2	COMPLETED
Open-Label Extension Study to Assess GLM101 in PMM2-CDG Patients	PHASE2	ENROLLING_BY_INVITATION
24-Week Study to Assess the PD, Safety, Tolerability, and PK of GLM101 in Participants With PMM2-CDG	PHASE2	COMPLETED
Safety, Efficacy Evaluation of Empagliflozin Administration for Neutropenia in Glycogenosis Type 1b and G6PC3 Deficiency	PHASE2	UNKNOWN
A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis	PHASE1/PHASE2	RECRUITING
Pharmacokinetic Interaction Study of Efavirenz and American Ginseng in Healthy Volunteers	PHASE1	COMPLETED
PK and PD of YG1699 in CKD Patients With Diabetes	PHASE1	NOT_YET_RECRUITING
Glycosylation in Patients With Galactosaemia	nan	COMPLETED
Intervention and Outcomes in Duarte Galactosemia	nan	COMPLETED
Pharmacogenetic Study in Patients Received Iron Chelating Agent	nan	COMPLETED
Role of Metabolic Enzymes in Non-Melanoma Skin Cancer	nan	COMPLETED
Using D-Galactose as a Food Supplement in Congenital Disorders of Glycosylation	nan	COMPLETED
A Retrospective Study to Identify New Omics Biomarkers of Chronic/Persistent Low Back Pain	nan	COMPLETED
Effect of an Polyphenolic Beverage in Healthy Volunteers	nan	ACTIVE_NOT_RECRUITING
Cross-Sectional and Longitudinal Studies of Pre-Diabetes in the Pima Indians	nan	COMPLETED
Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML)	nan	WITHDRAWN
Evaluation of Blood Protein O-GlcNAcylation Levels in Children	nan	RECRUITING
Identification and Characterization of Monogenic Diabetes	nan	COMPLETED
Evaluation of Blood and Cardiac Protein O-GlcNAcylation Levels in Cardiac Surgery in Children	nan	RECRUITING
Role of the Liver in Glucose Homeostasis Using Metabolic Imaging	nan	COMPLETED
EXpanding Prenatal Cell Free DNA Screening Across moNogenic Disorders (EXPAND)	nan	RECRUITING
Cardiovascular Disease (CVD) Risk and Prevention in Early Glucose Intolerance	nan	COMPLETED
1,5-AG as a Marker of Postprandial Hyperglycemia and Glucose Variability in Well-controlled Type 2 Diabetes Mellitus	nan	COMPLETED
Hepatic Substrate Flux Rates in Type 2 Diabetes	nan	ACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a UGGT1 binder may also engage these)

Protein	Name	Similarity
Q9JLA3	—	1.000	Q9JLA3 →
Q6P5E4	—	1.000	Q6P5E4 →
Q9NYU1	—	0.998	Q9NYU1 →
Q0WL80	—	0.997	Q0WL80 →
Q09332	—	0.992	Q09332 →
Q8W4J3	—	0.987	Q8W4J3 →
A0A8M1N5Y4	—	0.984	A0A8M1N5Y4 →
Q86S40	—	0.983	Q86S40 →
Q80TN4	—	0.983	Q80TN4 →
Q9WTZ2	—	0.983	Q9WTZ2 →
Q5ZKZ4	—	0.983	Q5ZKZ4 →
Q6AXS4	—	0.983	Q6AXS4 →
Q9Y2G8	—	0.983	Q9Y2G8 →
Q8WUM0	—	0.982	Q8WUM0 →
Q9STV0	—	0.982	Q9STV0 →
Q765A7	—	0.982	Q765A7 →
Q9FYH7	—	0.982	Q9FYH7 →
O64758	—	0.982	O64758 →
Q66J01	—	0.982	Q66J01 →
Q66GQ3	—	0.982	Q66GQ3 →
Q2KHZ2	—	0.981	Q2KHZ2 →
P81134	—	0.981	P81134 →
Q6NUA7	—	0.981	Q6NUA7 →
Q3UUQ7	—	0.981	Q3UUQ7 →
G5ED46	—	0.981	G5ED46 →
Q9LW26	—	0.980	Q9LW26 →
Q60432	—	0.980	Q60432 →
Q9Z2A8	—	0.980	Q9Z2A8 →
Q9WTZ3	—	0.980	Q9WTZ3 →
A1XD95	—	0.980	A1XD95 →